Crossmark

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Crossref DOI link: https://doi.org/10.1038/s41467-023-41828-z

Published Online: 2023-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Macaya, Irati https://orcid.org/0000-0001-5698-6452
Roman, Marta

Welch, Connor

Entrialgo-Cadierno, Rodrigo https://orcid.org/0000-0001-9682-6971
Salmon, Marina

Santos, Alba https://orcid.org/0000-0002-6257-9869
Feliu, Iker

Kovalski, Joanna https://orcid.org/0000-0001-8436-6656
Lopez, Ines

Rodriguez-Remirez, Maria

Palomino-Echeverria, Sara

Lonfgren, Shane M.

Ferrero, Macarena https://orcid.org/0000-0001-9470-9800
Calabuig, Silvia

Ludwig, Iziar A. https://orcid.org/0000-0001-5506-3293
Lara-Astiaso, David https://orcid.org/0000-0001-8686-4675
Jantus-Lewintre, Eloisa https://orcid.org/0000-0001-7395-4380
Guruceaga, Elizabeth https://orcid.org/0000-0003-0547-681X
Narayanan, Shruthi

Ponz-Sarvise, Mariano https://orcid.org/0000-0002-3240-729X
Pineda-Lucena, Antonio

Lecanda, Fernando

Ruggero, Davide https://orcid.org/0000-0002-9444-5865
Khatri, Purvesh https://orcid.org/0000-0002-4143-4708
Santamaria, Enrique https://orcid.org/0000-0001-8046-8102
Fernandez-Irigoyen, Joaquin https://orcid.org/0000-0001-5072-4099
Ferrer, Irene

Paz-Ares, Luis

Drosten, Matthias https://orcid.org/0000-0002-3205-456X
Barbacid, Mariano

Gil-Bazo, Ignacio https://orcid.org/0000-0002-2626-5109
Vicent, Silve https://orcid.org/0000-0002-9457-6881
Funding

Funding for this research was provided by:

Fundación Científica Asociación Española Contra el Cáncer (PROYE20029VICE)

Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2020‐116344‐RB‐100)
License Information

Text and Data Mining valid from 2023-10-10

Version of Record valid from 2023-10-10
More Information

Article History

Received: 13 December 2022

Accepted: 20 September 2023

First Online: 10 October 2023

Competing interests

: M.P.-S. reports personal fees from Incyte, Genentech, Hoffmann La Roche, TFS Health Science and Astra Zeneca; research funding from Roche and BMS; and travel grants from Incyte and BMS. F.L. and S.V. report research funding from Roche. S.V. discloses project funding from Revolution Medicines and advisor fees from Libera Bio. None of the disclosed information applies to the current project. No potential conflicts of interest were disclosed by the other authors.

Document is current

Any future updates will be listed below